[Evaluation of the hormonal status of patients with bronchial asthma by using various drug doses].

Drug loads were used to diagnose impairments of the hypothalamic-pituitary-adrenal system in 209 patients with bronchial asthma. A thyroid-releasing hormone test made in patients with moderate bronchial asthma who were taking no corticosteroids (CS) demonstrated a high level of thyroid-stimulating hormone at min 60 of the agent administration, which was indicative of decreased hypothalamic function. In 67.

[A comparative evaluation of methods of determining melanogen in the urine of patients with steroid-dependent bronchial asthma].

Fifty-four patients with steroid-dependent asthma of varying severity during exacerbation were examined to compare the efficacies of urinary melanogen measurement techniques. Jaksch's, Tormelen's methods, and the technique with 2M sulfuric acid were used. The tests were positive in but 3 (15%) patients with a medium severe course of the process and in 23 (68%) ones with a grave condition.

[The effect of injectable leukinferon on the immune reactivity of patients with steroid-dependent bronchial asthma].

The authors provide the results of the treatment with leukinferon for injections of 25 patients with steroid-dependent bronchial asthma. It is the authors' belief that leukinferon for injections may be recommended for introduction into multimodality schedules of the treatment of patients with the above-indicated pathology. The drug is tolerated well, without any phenomena of sensitization, when administered by inhalation in the form of aqueous aerosol in a dose of 10,000 IU/day.

[Analysis of the cause of death in patients with steroid-dependent bronchial asthma].

Description is given of 11 patients with a severe form of protracted corticosteroid-dependent asthma. They died in status asthmaticus. Most of these patients had protracted status asthmaticus and cardiopulmonary failure.

[Effect of prodigiozan on immune reactivity in patients with steroid-dependent bronchial asthma].

An optimum scheme of prodigiosan therapy was developed for patients with steroid-dependent bronchial asthma taking account of the hormonal and immunological status. First the drug was administered at a dose of 0.1 ml of 0.